While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.
First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque Psoriasis THOUSAND OAKS, Calif. , Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use.
The Dow Jones Industrial Average contains shares of 30 companies that lead their respective industries. Now that it no longer sells consumer goods, Johnson & Johnson's dividend growth rate could shift into a higher gear.
Amgen generated 20% revenue growth in its most recent quarter. The business has several fast-growing drugs showing double-digit growth despite generating over $200 million in quarterly sales.
Let's talk about recession-resistant dividends because, if history is any guide, we are certainly “on the clock” for a slowdown if not already in one. Here at Contrarian Outlook we have been preparing for slower economic readings, and our recession divvies have already delivered.
Amgen Inc., the Thousand Oaks headquartered Pharma giant, reported its Q2 2024 earnings on August 6th. My last coverage of Amgen was in May after Q1 earnings, and I awarded the stock a “buy” recommendation. Q2 earnings were generally solid, with the Horizon assets bedding in well, meaning revenues grew 20% year-on-year.
Times of higher uncertainty and elevated market volatility can provide investors with excellent opportunities to start building a dividend portfolio. The dividend portfolio I will present in today's article provides investors with broad diversification across sectors, with no sector accounting for more than 18% of the overall portfolio. This dividend portfolio delivers a Weighted Average Divide...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.